• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

NEC X Invests in GPx to Advance AI-Driven Chronic Disease Monitoring

by Syed Hamza Sohail 11/13/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– NEC X, the Silicon Valley venture studio backed by NEC’s portfolio of advanced technologies and global businesses, today announced a new investment in General Prognostics Inc.

– (GPx), a fast-growing MedTech startup revolutionizing chronic disease monitoring and management.

NEC X Invests in GPx to Advance Remote Blood Monitoring Solution for Heart Failure Patients

NEC X has invested in GPx as part of its strategic effort to foster healthcare innovation and address pressing challenges in chronic disease management. This investment aligns with NEC X’s vision of leveraging technology to improve healthcare access and reduce system burdens, particularly for patients with chronic conditions.

Coinciding with this investment, GPx has joined the Elev X! Boost program, a venture initiative designed to scale ambitious startups through a tailored blend of capital, strategic partnerships, and integrations within NEC X’s expansive tech ecosystem. Through Elev X! Boost, GPx will:

– Enhance the accuracy of its flagship product, **CardioID**—the world’s first implant- and needle-free remote blood monitoring solution for heart failure patients.

– Drive revenue growth, enter new markets, and secure further funding.

The CardioID system enables remote monitoring by extracting biomarkers from wearable devices, utilizing data such as heart rate, heart rate variability, step count, and voice. Through advanced machine learning, these biomarkers are analyzed to develop predictive models with accuracy exceeding that of traditional implant-based systems.

GPx’s leadership team brings robust expertise in healthcare and medical devices. The team, composed of graduates from MIT and Harvard, includes co-founders **Sean Matsuoka** and Javier Echenique, whose backgrounds span leadership roles at firms like Caresyntax, M3, McKinsey & Company, Sony Corporation, Jana Care, Medtronic, and Volcano. Founding advisor Sidhant Jena also contributes significant experience, having co-founded and led Jana Care as CEO and held R&D leadership roles at Medtronic.

This partnership with NEC X will accelerate GPx’s growth trajectory as it prepares to scale operations and bring CardioID to market, setting new standards for non-invasive, real-time cardiac monitoring.

“GPx’s innovative approach to heart monitoring and chronic disease management is a perfect fit for the NEC Group’s vision of leveraging advanced technology to improve quality of life,” said Shintaro Matsumoto, President and CEO of NEC X. “By joining forces with GPx, we aim to enhance their predictive algorithms and capabilities. Together, we can transform the healthcare industry.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Chronic Disease Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |